Ocugen NASDAQ: OCGN expects pivotal data for its lead experimental gene therapy for retinitis pigmentosa in the first quarter of 2027, a milestone that could set up a regulatory filing later that year, CEO Shankar Musunuri said at a company presentation.
MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and Celairis Therapeutics Holdings Pty Ltd. ("Celairis"), a Sydney-based in-licensing, development, and commercialization biopharmaceutical company focused on Australia, New Zealand, Taiwan, and ASEAN, today announced the execution of an exclusive license agreement (the "License Agreement") granting Celairis an exclusive license to commercialize OCU400, Ocugen's investigational modifier gene therapy for the treatment of RP, in Australia, New Zealand, and ASEAN markets (the "Territory").
OCGN's Q3 revenues beat estimates. Shares surge 17.4%.
Ocugen, Inc. ( OCGN ) Q3 2026 Earnings Call November 4, 2026 8:30 AM EST Company Participants Chris Clark - VP of Corporate Communications Shankar Musunuri - Co-Founder, CEO & Chairman Rita Johnson-Greene - CFO & Principal Accounting Officer Mohamed Genead - Chief Medical Officer Abhi Gupta - Executive Vice President of Commercial and Business Development Conference Call Participants Swayampakula Ramakanth - H.C. Wainwright & Co, LLC, Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Michael Okunewitch - Maxim Group LLC, Research Division Elemer Piros - Lucid Capital Markets, LLC, Research Division Leland Gershell - Oppenheimer & Co. Inc., Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Presentation Operator Good morning, and welcome to Ocugen's Third Quarter 2026 Financial Results and Business Update.
Ocugen NASDAQ: OCGN said its third-quarter progress centered on advancing three retinal gene therapy programs in late-stage development, expanding regional partnerships and establishing a European presence to support future commercialization efforts.
Ocugen (OCGN) came out with a quarterly loss of $0.06 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.07 per share a year ago.
Conference Call and Webcast Today at 8:30 a.m. ET Received Provisional Approval and Priority Designation for OCU400 in The Bahamas Executed agreement with local partner Global Alliance for Regenerative Medicine (GARM) to coordinate and manage patient care Progressing site readiness in preparation to accept patients Advancing toward full approval and potential patient enrollment as early as year-end Executed an exclusive OCU400 license agreement for the Middle East and North Africa (MENA) with Roots Pharmaceutical Initiated dosing in Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) Cash, cash equivalents, restricted cash, and short-term investments of $84.6 million as of September 30, 2026; with expected runway into 2028 MALVERN, Pa.
MALVERN, Pa., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology company developing gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor and industry conferences in November 2026.
MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, will host a conference call and live webcast on Wednesday, November 4, 2026, at 8:30 a.m. ET to provide a business update and report third quarter 2026 financial results. All related materials will be made available on the Ocugen investor website prior to the start of the call.
MALVERN, Pa., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the execution of a licensing agreement with Roots Pharmaceutical, and its strategic partner Al-Dhow International Holding, for the exclusive rights to OCU400, Ocugen's novel modifier gene therapy for the treatment of Retinitis Pigmentosa (RP), in the Middle East and North Africa (MENA) region.